Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC

Overdiagnosis and Overtreatment of Prostate Cancer

(2014) Stacy Loeb et al.   EUROPEAN UROLOGY

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up

(2014) Fritz H Schröder et al.   LANCET

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer

(2014) Ali Amin Al Olama et al.   NATURE GENETICS

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array

(2013) Rosalind A Eeles et al.   NATURE GENETICS

Risk stratification in prostate cancer screening

(2012) Monique J. Roobol et al.   Nature Reviews Urology

Polygenic susceptibility to prostate and breast cancer: implications for personalised screening

(2011) N Pashayan et al.   BRITISH JOURNAL OF CANCER

Use of Baseline Prostate-Specific Antigen Measurements to Personalize Prostate Cancer Screening

(2011) Stacy Loeb   EUROPEAN UROLOGY

Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening

(2011) Grace Hui-Min Wu et al.   INTERNATIONAL JOURNAL OF CANCER

High-throughput single nucleotide polymorphism genotyping using nanofluidic Dynamic Arrays

(2009) Jun Wang et al.   BMC GENOMICS

Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context

(2009) G. Draisma et al.   JNCI-Journal of the National Cancer Institute

Polygenes, Risk Prediction, and Targeted Prevention of Breast Cancer

(2008) Paul D.P. Pharoah et al.   NEW ENGLAND JOURNAL OF MEDICINE